Bioxytran, Inc. (BIXT) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
C/O BIOXYTRAN, INC. NEEDHAM, MA 02494 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)Annual | Quarterly
| 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 45,181 | 153,801 | 295,401 | 374,190 | 500,677 | 739,584 | |||
| Cash and cash equivalents | 45,181 | 153,801 | 295,401 | 374,190 | 500,677 | 739,584 | |||
| Total current assets: | 45,181 | 153,801 | 295,401 | 374,190 | 500,677 | 739,584 | |||
| Noncurrent Assets | |||||||||
| Intangible assets, net (including goodwill) | 97,880 | 79,732 | 75,535 | 74,349 | 67,548 | 68,343 | |||
| Intangible assets, net (excluding goodwill) | 97,880 | 79,732 | 75,535 | 74,349 | 67,548 | 68,343 | |||
| Total noncurrent assets: | 97,880 | 79,732 | 75,535 | 74,349 | 67,548 | 68,343 | |||
| TOTAL ASSETS: | 143,061 | 233,533 | 370,936 | 448,539 | 568,225 | 807,927 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 562,662 | 1,100,869 | 749,395 | 341,511 | 556,835 | 516,139 | |||
| Accounts payable | 200,500 | 975,227 | |||||||
| Accrued liabilities | 561,116 | 1,098,409 | 748,405 | 80,951 | 121,893 | 120,696 | |||
| Other undisclosed accounts payable and accrued liabilities | (198,954) | (972,767) | 990 | 260,560 | 434,942 | 395,443 | |||
| Debt | 2,000,000 | 2,165,000 | 2,165,000 | 2,157,510 | 3,593,650 | 3,552,225 | |||
| Deferred compensation liability | 380 | 1,810 | 960 | 900 | 60,150 | ||||
| Due to related parties | ✕ | ✕ | ✕ | 709,727 | 461,727 | 1,062,000 | 796,506 | ||
| Other liabilities | 975,227 | ||||||||
| Other undisclosed current liabilities | 206,200 | 51,150 | 38,400 | 36,000 | 56,240 | 22,400 | |||
| Total current liabilities: | 2,769,242 | 4,294,056 | 3,663,482 | 2,997,648 | 5,328,875 | 4,887,270 | |||
| Noncurrent Liabilities | |||||||||
| Total liabilities: | 2,769,242 | 4,294,056 | 3,663,482 | 2,997,648 | 5,328,875 | 4,887,270 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (2,001,896) | (3,437,001) | (2,701,918) | (2,009,539) | (4,760,650) | (4,079,343) | |||
| Common stock | 132,035 | 123,502 | 123,252 | 123,014 | 110,841 | 110,841 | |||
| Additional paid in capital | 11,279,970 | 8,442,180 | 8,392,430 | 8,279,376 | 5,876,859 | 5,924,126 | |||
| Accumulated deficit | (13,413,901) | (12,002,683) | (11,217,600) | (10,411,929) | (10,288,287) | (9,665,938) | |||
| Other undisclosed equity, attributable to parent | (460,063) | (448,372) | |||||||
| Equity, attributable to noncontrolling interest | (624,286) | (623,522) | (590,628) | (539,570) | |||||
| Total equity: | (2,626,182) | (4,060,523) | (3,292,546) | (2,549,109) | (4,760,650) | (4,079,343) | |||
| TOTAL LIABILITIES AND EQUITY: | 143,060 | 233,533 | 370,936 | 448,539 | 568,225 | 807,927 | |||
Income Statement (P&L) (USD)Annual | Quarterly
| 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (1,021,680) | (750,242) | (792,008) | 14,225 | (537,224) | (819,106) | ||
| Operating income (loss): | (1,021,680) | (750,242) | (792,008) | 14,225 | (537,224) | (819,106) | ||
| Nonoperating expense | (390,302) | (67,735) | (64,722) | (217,374) | (96,816) | (144,280) | ||
| Interest and debt expense | (52,035) | |||||||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 52,035 | |||||||
| Loss from continuing operations: | (1,411,982) | (817,977) | (856,730) | (203,149) | (634,040) | (963,386) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (203,149) | (634,040) | (963,386) | |
| Other undisclosed net income | 51,316 | |||||||
| Net loss: | (1,411,982) | (817,977) | (856,730) | (203,149) | (634,040) | (912,070) | ||
| Net income attributable to noncontrolling interest | 764 | 32,894 | 51,058 | 79,507 | 11,691 | 51,116 | ||
| Other undisclosed net loss attributable to parent | (102,432) | |||||||
| Net loss attributable to parent: | (1,411,218) | (785,083) | (805,672) | (123,642) | (622,349) | (963,386) | ||
| Other undisclosed net income available to common stockholders, basic | 51,116 | |||||||
| Net loss available to common stockholders, diluted: | (1,411,218) | (785,083) | (805,672) | (123,642) | (622,349) | (912,270) | ||
Comprehensive Income (USD)Annual | Quarterly
| 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (1,411,982) | (817,977) | (856,730) | (203,149) | (634,040) | (912,070) | ||
| Comprehensive loss: | (1,411,982) | (817,977) | (856,730) | (203,149) | (634,040) | (912,070) | ||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 764 | 32,894 | 51,058 | 79,507 | 11,691 | 51,116 | ||
| Comprehensive loss, net of tax, attributable to parent: | (1,411,218) | (785,083) | (805,672) | (123,642) | (622,349) | (860,954) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.